HCW Biologics Reports Revenue Growth to $6.7 Million and Narrows Net Loss in Latest Filing

HCW Biologics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $6.7 million for the six months ended June 30, 2026, a substantial increase from $11,615 during the same period in 2025. This growth was primarily driven by the completion of services under the Trimmune License, which included a nonrefundable upfront license fee of $3.5 million. However, the company also reported a net loss of $1.7 million for the six months, compared to a loss of $4.1 million in the prior year, indicating a narrowing of losses.

In terms of operational changes, HCW Biologics underwent a reverse stock split on June 30, 2026, at a ratio of one-for-six, which adjusted the number of shares outstanding to 1,617,642. The company also terminated its exclusive license agreement with AlloTera Therapeutics, allowing it to reposition its previously licensed molecules as commercial-ready reagents for immunotherapy manufacturing. This strategic shift is expected to enhance the company's market position in the biopharmaceutical sector.

The company’s total assets increased to $26.8 million as of June 30, 2026, up from $24.5 million at the end of 2025. This growth was supported by a rise in investments, which surged from $1.3 million to $4.9 million. However, total liabilities also decreased from $21.8 million to $19.3 million, reflecting a reduction in accounts payable and short-term debt. The company’s cash and cash equivalents stood at $741,324, down from $1.95 million at the end of 2025, indicating a tightening liquidity position.

HCW Biologics reported a decrease in research and development expenses, which fell to $2.5 million for the six months ended June 30, 2026, compared to $2.7 million in the prior year. This reduction was attributed to lower manufacturing costs and clinical trial expenses. General and administrative expenses also decreased by 14% to $3.7 million, primarily due to lower salaries and benefits expenses. The company continues to face challenges, including ongoing operating losses and a need for additional funding to support its clinical development activities.

Looking ahead, HCW Biologics anticipates continued investment in its clinical programs, particularly for its lead product candidates, HCW9302 and HCW11-018b. The company is preparing for a Phase 1 clinical trial for HCW11-018b, expected to initiate in the first half of 2027, contingent upon FDA authorization. Despite the challenges, the company remains focused on advancing its innovative therapies aimed at treating chronic inflammatory diseases and cancer.